Alessandro Rametta

Nationality: Italian **Date of birth:** 24/01/1992 ✉ **Email address:** alessandro.rametta@istitutotumori.mi.it

WORK EXPERIENCE

Volunteer in a Hospital as Medical Student
Amici di Ampasilava [11/2015 – 12/2015]

City: Andavadoaka | **Country:** Madagascar

Emergency Medical Service
Azienda USL Toscana Nord-Ovest [02/2017 – 03/2018]

City: Pisa | **Country:** Italy

Oncologist
IRCCS Istituto Nazionale Tumori di Milano - Oncologia Genitourinaria [01/12/2023 – Current]

City: Milano | **Country:** Italy

EDUCATION AND TRAINING

Secondary school Certificate
Liceo Scientifico Ulisse Dini [2005 – 2010]

City: Pisa

Degree in Medicine and Surgery
Università degli Studi di Pisa [2010 – 2016]

City: Pisa | **Country:** Italy

Oncology Residency
Università degli studi di Milano - IRCCS Istituto Nazionale Tumori di Milano [01/11/2018 – 31/10/2023]

City: Milan | **Country:** Italy

ESMO Examination
ESMO [2022]

ESMO Preceptorship in Kidney and Bladder Cancer
ESMO [27/03/2023 – 28/03/2023]

City: Lugano | **Country:** Switzerland

Observership in Genitourinary Group
Vall d'Hebron Institute of Oncology (VHIO) [11/04/2023 – 28/09/2023]

City: Barcelona | **Country:** Spain | **Website:** https://vhio.net/

LANGUAGE SKILLS

Mother tongue(s): Italian

Other language(s):

English	**Spanish**
LISTENING B2 **READING** B2 **WRITING** B1	**LISTENING** B1 **READING** B2 **WRITING** A2
SPOKEN PRODUCTION B2 **SPOKEN INTERACTION** B2	**SPOKEN PRODUCTION** B1 **SPOKEN INTERACTION** B1

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

PUBLICATIONS

[2022]
The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma

[2021]
COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study

[2022]
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison

[2023]
Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma

[2023]
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients

[2023]
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?

[2023]
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study

[2023]
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score

[2024]
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)

[2024]
Impressive and Prolonged Response with Lenvatinib in a Highly Pretreated Patient with Metastatic Clear Cell Renal Cancer: A Case Report

[2023]
Long-Term Response after Early Discontinuation Due to Immunotherapy Toxicity In Metastatic Renal Cancer: A Clinical Case and Literature Review

CONFERENCES AND SEMINARS

[17/11/2022 – 18/11/2022] IRCCS Istituto Nazionale Tumori di Milano

Masterclass in Prostate Cancer - From Diagnosis to Treatment Presentation of interactive clinical prostate cancer case

[05/11/2021] Brescia
Le Neoplasie Genitourinarie: tra pratica clinica e innovazione Presentation about immunotherapy in Urothelial Cancer

[23/09/2021] IRCCS Istituto Nazionale Tumori di Milano
Controversies in GU Presentation about second generation ARi in prostate cancer